Savara Pharmaceuticals Home - Savara Pharmaceuticals

We focus on rare respiratory diseases in order to give patients with unmet medical needs better treatment options.

We are advancing a pipeline of novel inhalation therapies for the treatment of severe pulmonary conditions.

Savara is currently conducting a Phase 3 clinical trial of Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) worldwide.

Savara is also conducting a pivotal Phase 3 study, AVAIL, of AeroVanc for the treatment of MRSA in Cystic Fibrosis patients in the U.S. and Canada.

Visit the AeroVanc website to learn more about MRSA in Cystic Fibrosis, AeroVanc and our pivotal Phase 3 AVAIL study

aerovanc

Visit our PAP portal where patients and doctors can learn more about this disease